NIH announces strategy for developing COVID-19 drugs, vaccines
April 21, 2020
Drug companies will collaborate across hundreds of clinical trials in effort to coordinate private coronavirus research, which has been marked by chaos thus far
The National Institutes of Health announced an initiative Friday to unify disparate efforts across the drug industry to respond to the coronavirus-related pandemic.
Pharmaceutical companies will collaborate across hundreds of COVID-19 clinical trials, the NIH says, by sharing “master protocols” on how those clinical trials will work.
“Collaboration is a critical ingredient for success and the FDA will continue to use every tool possible under our Coronavirus Treatment Acceleration Program to speed the development of safe and effective medical countermeasures,” said Food and Drug Administration Commissioner Stephen Hahn in a statement.
The coronavirus-related research race has been thus far marked by chaos as dozens of private companies and researchers compete for a cure, according to a recent news report.
Read the full article by Emily Kopp below.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
